AD04

About Adial Pharmaceuticals

Adial Pharmaceuticals is focused on developing genetically targeted therapies for addiction, with an initial emphasis on Alcohol Use Disorder (AUD). The company's core achievement is advancing its lead candidate, AD04, into Phase 3 trials, supported by a proprietary companion diagnostic to identify optimal patient responders. Its strategy hinges on leveraging precision medicine to improve treatment efficacy and secure a differentiated position in the addiction therapeutics market, while navigating regulatory pathways and exploring strategic partnerships for commercialization.

About ADvantage Therapeutics

ADvantage Therapeutics is pioneering a novel immunotherapy approach for Alzheimer's Disease with its lead candidate, AD04™, a compound with an established safety profile from its prior use as a vaccine adjuvant. Unexpected Phase 2 data revealed AD04™ significantly slowed cognitive decline and hippocampal atrophy in early AD patients, forming the basis for the company's founding. The company is now advancing AD04™ into further Phase 2 trials in Europe, supported by an MHRA ILAP Passport in the UK, which could enable early commercialization. ADvantage's pipeline also includes research into the longevity protein Klotho, aiming to develop first-in-class therapeutics for diseases of aging.

Therapeutic Areas